JPS6339572B2 - - Google Patents
Info
- Publication number
- JPS6339572B2 JPS6339572B2 JP52016498A JP1649877A JPS6339572B2 JP S6339572 B2 JPS6339572 B2 JP S6339572B2 JP 52016498 A JP52016498 A JP 52016498A JP 1649877 A JP1649877 A JP 1649877A JP S6339572 B2 JPS6339572 B2 JP S6339572B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- add
- substance
- water
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000243 solution Substances 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 12
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 12
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- FPFSGDXIBUDDKZ-UHFFFAOYSA-N 3-decyl-2-hydroxycyclopent-2-en-1-one Chemical compound CCCCCCCCCCC1=C(O)C(=O)CC1 FPFSGDXIBUDDKZ-UHFFFAOYSA-N 0.000 claims description 6
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- XIWMTQIUUWJNRP-UHFFFAOYSA-N amidol Chemical compound NC1=CC=C(O)C(N)=C1 XIWMTQIUUWJNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000011609 ammonium molybdate Substances 0.000 claims description 6
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 claims description 6
- 229940010552 ammonium molybdate Drugs 0.000 claims description 6
- 235000018660 ammonium molybdate Nutrition 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000002331 protein detection Methods 0.000 claims description 6
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 6
- 239000003463 adsorbent Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000001624 sedative effect Effects 0.000 claims description 2
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 claims 5
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010049040 Weight fluctuation Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1649877A JPS53101515A (en) | 1977-02-17 | 1977-02-17 | Medicine having anodyne * sedative and antiallergic activity and production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1649877A JPS53101515A (en) | 1977-02-17 | 1977-02-17 | Medicine having anodyne * sedative and antiallergic activity and production thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS53101515A JPS53101515A (en) | 1978-09-05 |
| JPS6339572B2 true JPS6339572B2 (fr) | 1988-08-05 |
Family
ID=11917938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1649877A Granted JPS53101515A (en) | 1977-02-17 | 1977-02-17 | Medicine having anodyne * sedative and antiallergic activity and production thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS53101515A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1557171A1 (fr) | 2002-10-31 | 2005-07-27 | VanWorld Pharmaceutical (Rugao) Company Limited | Peau de lapin comprenant une substance bioactive et son utilisation |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5835117A (ja) * | 1981-08-25 | 1983-03-01 | Nippon Zoki Pharmaceut Co Ltd | 新規生理活性物質ｎｓｈ |
| JPS59118711A (ja) * | 1982-12-25 | 1984-07-09 | Nippon Zoki Pharmaceut Co Ltd | 新規生理活性物質 |
| JP2651674B2 (ja) * | 1987-07-23 | 1997-09-10 | 日本臓器製薬 株式会社 | 新規生理活性物質及びその製造方法 |
| JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
| JP2588109B2 (ja) * | 1993-03-19 | 1997-03-05 | 日本臓器製薬株式会社 | 鎮痛剤 |
| JP3213832B2 (ja) * | 1993-08-06 | 2001-10-02 | 日本臓器製薬株式会社 | 被検物質の活性測定法 |
| JP3213831B2 (ja) * | 1993-08-06 | 2001-10-02 | 日本臓器製薬株式会社 | 被検物質の活性測定方法 |
| JP2594222B2 (ja) * | 1993-09-28 | 1997-03-26 | 日本臓器製薬株式会社 | 新規生理活性物質−ｋｆ |
| JP4033936B2 (ja) * | 1997-01-08 | 2008-01-16 | 日本臓器製薬株式会社 | 一酸化窒素産生抑制剤 |
| JPH1180005A (ja) * | 1997-09-12 | 1999-03-23 | Nippon Zoki Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
| KR19990044835A (ko) | 1997-11-28 | 1999-06-25 | 고니시 진우에몬 | 생약추출물 |
| CN1272365A (zh) | 1999-04-15 | 2000-11-08 | 日本脏器制药株式会社 | 新型生理活性物质 |
| CA2337484A1 (fr) | 2000-02-18 | 2001-08-18 | Jin-Emon Konishi | Composition contenant un acide gras |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| TWI342778B (en) * | 2002-10-31 | 2011-06-01 | Nippon Zoki Pharmaceutical Co | Therapeutic agent for fibromyalgia |
| KR101307999B1 (ko) | 2004-12-01 | 2013-09-12 | 니폰 조키 세야쿠 가부시키가이샤 | 건조물 및 그 제조방법 |
| US20060134646A1 (en) | 2004-12-17 | 2006-06-22 | Ansari Aftab A | Method for treatment of HIV infection |
| TWI406664B (zh) | 2006-03-30 | 2013-09-01 | Univ Kyoto | 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑 |
| JPWO2008029836A1 (ja) * | 2006-09-06 | 2010-01-21 | 日本臓器製薬株式会社 | 研究、判定又は評価法 |
| CA2698129A1 (fr) | 2007-08-31 | 2009-03-05 | Kyushu University, National University Corporation | Agent destine a la prophylaxie ou au soulagement d'un trouble nerveux peripherique induit par un agent anti-cancereux |
| TWI483729B (zh) | 2010-03-11 | 2015-05-11 | Nippon Zoki Pharmaceutical Co | 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑 |
| TWI504894B (zh) | 2010-06-25 | 2015-10-21 | Nippon Zoki Pharmaceutical Co | 被檢物質的判定或評價方法 |
| EP2627343B1 (fr) | 2010-10-14 | 2018-01-10 | Nippon Zoki Pharmaceutical Co., Ltd. | Agents pour l'utilisation pour favoriser la synthèse de collagène et de protéoglycane dans les cellules intervertebrales |
| PL2855506T3 (pl) | 2012-05-25 | 2017-11-30 | Well Resources Limited | Peptydy i ich zastosowanie |
| TWI737229B (zh) | 2013-04-30 | 2021-08-21 | 日商日本臟器製藥股份有限公司 | 製劑的製造方法、製劑製造的管理方法及製劑的檢查方法 |
| US11129976B2 (en) | 2016-02-24 | 2021-09-28 | Osaka University | Test method |
| JP7125733B2 (ja) * | 2016-09-14 | 2022-08-25 | 日本臓器製薬株式会社 | 肢端紅痛症の改善又は治療剤 |
| US11207354B2 (en) | 2016-09-23 | 2021-12-28 | Osaka University | Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent |
-
1977
- 1977-02-17 JP JP1649877A patent/JPS53101515A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1557171A1 (fr) | 2002-10-31 | 2005-07-27 | VanWorld Pharmaceutical (Rugao) Company Limited | Peau de lapin comprenant une substance bioactive et son utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS53101515A (en) | 1978-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6339572B2 (fr) | ||
| JP2539665B2 (ja) | 神経疾患治療剤 | |
| Richter | The inactivation of adrenaline in vivo in man | |
| KR100189144B1 (ko) | 신규 생리 활성 물질 | |
| JP2651674B2 (ja) | 新規生理活性物質及びその製造方法 | |
| US5807951A (en) | Pharmaceutical composition regulating function of a living body | |
| JPS6312846B2 (fr) | ||
| CN104474551B (zh) | 褪黑素磷脂复合物、其透皮给药制剂及其制备方法 | |
| JP2539669B2 (ja) | 糖尿病性神経障害治療剤 | |
| EA029649B1 (ru) | Гель на основе полифенолов гранатовой кожуры для лечения воспалительных заболеваний в гинекологии и способ его приготовления | |
| JPH0343279B2 (fr) | ||
| CN106511512A (zh) | 一种中药外用凝胶及其制备方法与应用 | |
| JP2732379B2 (ja) | 知覚異常改善剤 | |
| US6726932B2 (en) | Fatty acid-containing composition | |
| CN110664860B (zh) | 一种增强免疫力的组合物及其制备方法 | |
| WO2024021826A1 (fr) | Composition pharmaceutique pour le traitement de la douleur cancéreuse et sa méthode de préparation | |
| CN103933100A (zh) | 功劳木总生物碱的制备及其在预防和治疗胃溃疡药物中的应用 | |
| CN103948726B (zh) | 治疗牛皮癣、真菌感染性皮肤病的外用中药及其制备方法 | |
| CN1325055C (zh) | 甜叶甙r1及其衍生物在制备防治帕金森病的药物中的应用 | |
| JP4995727B2 (ja) | 早漏治療用薬剤の製造のためのウインターセイボリー（ｓａｔｕｒｅｊａｍｏｎｔａｎａ）またはその抽出物の使用 | |
| WO2017114379A1 (fr) | Composition de gel nasal pour traiter la sclérose en plaques | |
| JPS59118711A (ja) | 新規生理活性物質 | |
| CN1424315A (zh) | 银杏内酯化合物及其制备方法和含有该化合物的药物组合物 | |
| CN1891216A (zh) | 儿茶精及其衍生物作为制备防治神经退行性疾病的药物的应用 | |
| CN106309454A (zh) | Friedolanostanes在制备治疗缺血性脑损伤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |